Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025.
LLY
· Healthcare · Drug Manufacturers - General
· Market cap $882.78B
QuantHub Original Research · Updated 2026-05-01
·
High QualityHigh-tier business, mid-tier valuationFair Value
LLY is trading near fair value. No urgent action needed.
QuantHub Research: Investment Thesis
Investing Phase
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat supported by strong management under CEO David A. Ricks, who has led the company since 2017. Despite a premium valuation with a trailing P/E of 33.07 and P/FCF of 65.01, the stock is fairly priced relative to its five-year history and offers nearly 99% upside to a fair value estimate of $1855.91. The company’s recent quarter showed exceptional growth with revenue up 55.5% and earnings up 168% year-over-year, reflecting strong execution and market demand. Risks include intense competition from Novo Nordisk, supply constraints, and regulatory challenges, but the company’s robust pipeline and capital allocation support a positive outlook.
Eli Lilly trades at a premium multiple with a trailing P/E of 33.07 and EV/EBITDA of 27.93, reflecting strong growth expectations driven by its GLP-1 franchise. The stock is considered fairly valued based on its five-year history despite high multiples, as the market prices in robust revenue growth and earnings momentum. Analyst consensus is a strong buy, but the absence of a consensus price target and the premium valuation suggest some caution. The nearly 99% upside to fair value indicates the market may be underestimating the company's growth potential or over-discounting competitive risks.
12–18 Month Outlook
In 18 months, Eli Lilly is expected to continue growing revenue significantly, with 2026 guidance raised to $80-83 billion driven by strong demand for GLP-1 drugs and oncology expansion. The company faces risks from competition and supply constraints but is positioned to maintain market leadership and potentially increase earnings if execution remains strong.
Bull vs Bear
Bull Case
Eli Lilly leads the obesity and diabetes markets with its GLP-1 drugs Mounjaro and Zepbound, which generated $36.5 billion in FY2025 and grew 99% year-over-year.
The company achieved record revenue of $65.2 billion in 2025, becoming the largest pharmaceutical company globally by revenue.
Strong quarterly growth with revenue up 55.5% and earnings up 168% year-over-year in the most recent quarter demonstrates robust operational execution.
Management under CEO David A. Ricks has a proven track record with nearly 25 years at the company and a strong capital allocation approach.
Raised 2026 revenue guidance to $80-83 billion reflects confidence in continued growth and new product launches.
Bear Case
Intense competition from Novo Nordisk in the GLP-1 obesity and diabetes market could pressure pricing and market share.
Supply shortages and manufacturing disruptions may limit the ability to meet high demand for key products.
High valuation multiples such as a P/FCF of 65.01 increase downside risk if growth slows or guidance is missed.
Regulatory risks including approvals, compliance issues, and government investigations could impact operations and costs.
Dependence on third-party relationships and potential supply chain issues pose operational risks.
Leadership & Competitive Position
David A. Ricks
Tenure7 yrs
Beats guidance75% of qtrs
Capital allocationFair
David A. Ricks has been CEO since 2017 and has a long tenure at Eli Lilly with diverse leadership roles. He has overseen the company’s expansion in diabetes and obesity markets and received $29.2 million in total compensation in 2024. Specific capital allocation metrics such as buybacks and dividends are not detailed, limiting a full assessment.
Competitive Moat
stable
intangible assetsbrandcost advantage
Eli Lilly holds a leading position in the GLP-1 obesity and diabetes markets with blockbuster drugs Mounjaro and Zepbound generating $36.5 billion in FY2025. Specific market share percentages are not available.
Competitors: Novo Nordisk (NVO)
Disruption: Medium due to competitive pressures from Novo Nordisk and potential regulatory challenges.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
33.07x
71.61x
56.25x
33.07x
244.54x
P/S
12.22x
15.77x
13.89x
9.08x
22.98x
P/FCF
65.01x
72.83x
42.0x
18.26x
338.24x
P/S 12.22x vs 5yr range 9.08-22.98x (P25=11.43x, median=13.89x, P75=16.48x)
Eli Lilly is expected to report full-year 2026 results with revenue guidance of $80-83 billion, which will provide insight into growth trajectory and execution on new product launches.
high
2026-Q2
Oncology Asset Integration
The $7 billion acquisition of cancer assets will begin contributing to revenue and may enhance the company’s oncology pipeline and market position.
medium
2026-Q3
Potential Stock Split Announcement
Due to the high share price and growth confidence, a stock split could improve liquidity and attract more retail investors.
low
Risks
Competitive Threats
high
Novo Nordisk and other rivals pose significant competition in the obesity and diabetes markets, which could pressure pricing and market share.
Supply and Manufacturing Constraints
high
High demand for key products may outpace supply capacity, leading to shortages and lost sales opportunities.
Regulatory and Compliance Risks
medium
Approvals, government investigations, and manufacturing compliance issues could disrupt operations and increase costs.
Valuation Risk
medium
High valuation multiples increase downside risk if growth slows or market sentiment shifts.
Growth Engines
GLP-1 Diabetes Drugsscaling
The diabetes and obesity markets are large and growing, with Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound driving nearly $36.5 billion in revenue in FY2025 and expected to expand further.
Oncology Portfoliomature
Oncology contributes approximately $5 billion in trailing twelve months revenue, with steady performance and recent $7 billion asset acquisitions signaling growth potential.
Immunology Segmentearly
Immunology generated $942 million in the latest trailing twelve months, representing a smaller but growing part of the portfolio.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.
Frequently Asked Questions
Is LLY undervalued?
LLY is currently fairly valued at $1,144.03 vs. our fair value estimate of $1,098.43 (-4% upside).
What is LLY's fair value?
QuantHub Research estimates LLY's fair value at $1,098.43 based on our proprietary valuation model incorporating historical P/S, P/E, and P/FCF multiples over a 5-year range.
What are the key risks for LLY?
Competitive Threats: Novo Nordisk and other rivals pose significant competition in the obesity and diabetes markets, which could pressure pricing and market share. Supply and Manufacturing Constraints: High demand for key products may outpace supply capacity, leading to shortages and lost sales opportunities. Regulatory and Compliance Risks: Approvals, government investigations, and manufacturing compliance issues could disrupt operations and increase costs.
What is the bull case for LLY?
Eli Lilly leads the obesity and diabetes markets with its GLP-1 drugs Mounjaro and Zepbound, which generated $36.5 billion in FY2025 and grew 99% year-over-year. The company achieved record revenue of $65.2 billion in 2025, becoming the largest pharmaceutical company globally by revenue. Strong quarterly growth with revenue up 55.5% and earnings up 168% year-over-year in the most recent quarter demonstrates robust operational execution. Management under CEO David A. Ricks has a proven track reco